Psilocybin paired with psychotherapy is associated with a robust and sustained decrease in drinking among adults with alcohol use disorder (AUD), new research suggests. Results from the first randomized, placebo-controlled trial of psilocybin for alcohol dependence showed that during the 8 months after first treatment dose, participants who received psilocybin had less than half […]
Question Does antiplatelet therapy administered to critically ill patients with COVID-19 improve organ support–free days (a composite end point of in-hospital mortality and duration of intensive care unit–based respiratory or cardiovascular support) up to day 21? Findings In this bayesian randomized clinical trial that included 1557 patients, antiplatelet therapy with either aspirin […]
Among patients with elevated soluble urokinase plasminogen receptor levels, standard care plus anakinra increased full recovery and lowered mortality compared with standard care alone. Identifying patients at excess risk for severe COVID-19 is critical for devising treatment strategies (particularly those involving immune modulation) where early therapy is important. One predictor […]
Antithrombotic therapy in clinically stable, nonhospitalized COVID-19 patients does not offer protection against adverse cardiovascular or pulmonary events, new randomized clinical trial results suggest. Antithrombotic therapy has proven useful in acutely ill inpatients with COVID-19, but in this study, treatment with aspirin or apixaban (Eliquis) did not reduce the rate of all-cause mortality, symptomatic […]
